SHP-1 and SHP-2 gene expressions in leukemia and unclassified blood disorders

Nguyen Thi May; Nguyen Thi Xuan

doi:10.15625/2615-9023/v42n4.14613

Author affiliations

Authors

Nguyen Thi May
Nguyen Thi Xuan https://orcid.org/0000-0003-3494-5136

DOI:

https://doi.org/10.15625/2615-9023/v42n4.14613

Keywords:

Blood diseases, blood disorder, disease diagnosis, gene expressions.

Abstract

Hematopoiesis and blood diseases include leukemia and unclassified blood disorders (UBDs). Leukemia, one of the leading causes of cancer death in the world, is divided into four major types including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The SHP gene group belongs to the protein tyrosine phosphatase (PTP) family, which plays an important role in preventing cancer growth. This group consists of two main genes, SHP-1 and SHP-2. In this study, experiments were conducted to determine the expression of SHP-1 and SHP-2 genes in patients with leukemia and UBDs using real-time PCR. Results showed that while SHP-1 gene expression was significantly decreased in all patient samples compared to control samples, SHP-2 gene expression was significantly increased in patients with CML and other blood disorders but decreased in ALL patients compared to healthy subjects. These results are important for disease diagnosis and combination therapy based on SHP-1 and SHP-2 target genes.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Amin S., Kumar A., Nilchi L., Wright K., Kozlowski M., 2011. Breast cancer cells proliferation is regulated by tyrosine phosphatase SHP1 through c-jun N-terminal kinase and cooperative induction of RFX-1 and AP-4 transcription factors. Mol. Cancer Res., 9: 1112–1125.

Beldi-Ferchiou A., Skouri N., Ben Ali C., Safra I., Abdelkefi A., Ladeb S., Mrad K., Ben Othman T., Ben Ahmed M., 2017. Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma. PloS one, 12: e0174835.

Chan G., Cheung L. S., Yang W., Milyavsky M., Sanders A. D., Gu S., Hong W. X., Liu A. X., Wang X., Barbara M., Sharma T., Gavin J., Kutok J. L., Iscove N. N., Shannon K. M., Dick J. E., Neel B. G., Braun B. S., 2011. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood, The Journal of the American Society of Hematology, 117: 4253–4261.

Chan R. J., Li Y., Hass M. N., Walter A., Voorhorst C. S., Shelley W. C., Yang Z., Orschell C. M., Yoder M. C., 2006. Shp-2 heterozygous hematopoietic stem cells have deficient repopulating ability due to diminished self-renewal. Experimental hematology, 34: 1230–1239.

Chim C. S., Fung T. K., Cheung W. C., Liang R., Kwong Y. L., 2004. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood, 103: 4630–4635.

Dong Q., Siminovitch K. A., Fialkow L., Fukushima T., Downey G. P., 1999. Negative regulation of myeloid cell proliferation and function by the SH2 domain-containing tyrosine phosphatase-1. J. Immunol, 162: 3220–3230.

Gauffin F., Diffner E., Gustafsson B., Nordgren A., Wingren A. G., Sander B., Persson J. L., Gustafsson B., 2009. Expression of PTEN and SHP1, investigated from tissue microarrays in pediatric acute lymphoblastic, leukemia. Pediatric hematology and oncology, 26: 48–56.

Haque S. J., Harbor P., Tabrizi M., Yi T., Williams B. R., 1998. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction. J. Biol. Chem., 273: 33893–33896.

Li Y., Yang L., Pan Y., Yang J., Shang Y., Luo J., 2014. Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia. Oncology reports, 31: 2438–2446.

Liu J., Wang Y., Sun X., Ji N., Sun S., Wang Y., Liu F., Cui Q., Wang C., Liu Y., 2017a. Promoter methylation attenuates SHP1 expression and function in patients with primary central nervous system lymphoma. Oncology reports, 37: 887–894.

Liu J., Zheng Y., Gao J., Zhu G., Gao K., Zhang W., Shi F., Zhang Q., 2017b. Expression of SHP-1 and SOCS6 in patients with acute leukemia and their clinical implication. Onco Targets Ther, 10: 1915–1920.

Loh M. L., Vattikuti S., Schubbert S., Reynolds M. G., Carlson E., Lieuw K. H., Cheng J. W., Lee C. M., Stokoe D., Bonifas J. M., Curtiss N. P., Gotlib J., Meshinchi S., Le Beau M. M., Emanuel P. D., Shannon K. M., 2004. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood, 103: 2325–2331.

Lorenz U., 2009. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev, 228: 342–359.

Pandey R., Saxena M., Kapur R., 2017. Role of SHP2 in hematopoiesis and leukemogenesis. Curr Opin Hematol, 24: 307–313.

Plutzky J., Neel B. G., Rosenberg R. D., Eddy R. L., Byers M. G., Jani-Sait S., Shows T. B., 1992. Chromosomal localization of an SH2-containing tyrosine phosphatase (PTPN6). Genomics, 13: 869–872.

Poole A. W., Jones M. L., 2005. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal, 17: 1323–1332.

Tartaglia M., Niemeyer C. M., Fragale A., Song X., Buechner J., Jung A., Hahlen K., Hasle H., Licht J. D., Gelb B. D., 2003. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature genetics, 34: 148–150.

Tonks N. K., 2006. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol, 7: 833–846.

Wickrema A., Chen F., Namin F., Yi T., Ahmad S., Uddin S., Chen Y. H., Feldman L., Stock W., Hoffman R., Platanias L.

C., 1999. Defective expression of the SHP-1 phosphatase in polycythemia vera. Experimental hematology, 27: 1124–1132.

Wu C., Sun M., Liu L., & Zhou G. W., 2003. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene, 306: 1–12.

Xu R., Yu Y., Zheng S., Zhao X., Dong Q., He Z., Liang Y., Lu Q., Fang Y., Gan X., Xu X., Zhang S., Dong Q., Zhang X., Feng G.-S., 2005a. Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood, 106: 3142–3149.

Xu R., Yu Y., Zheng S., Zhao X., Dong Q., He Z., Liang Y., Lu Q., Fang Y., Gan X., Xu X., Zhang S., Dong Q., Zhang X., Feng G.S., 2005b. Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood, 106: 3142–3149.

Yang W., Klaman L. D., Chen B., Araki T., Harada H., Thomas S. M., George E. L., Neel B. G., 2006. An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. Dev. Cell, 10:

–327.